|
|
|
Asthma Global Clinical Trials Review, H2, 2011
12/31/2011 | published by: GlobalData
Asthma Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Asthma Global Clinical Trials Review, H2, 2011 provides data on the Asthma clinical trial scenario. This report provides elemental information and data relating to the
|
more...
|
$1,000.00
|
|
Asthma – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Asthma – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Asthma - Pipeline Review, H1 2012', provides an overview of the Asthma therapeutic pipeline. This report provides information on the therapeutic development for Asthma, complete with latest
|
more...
|
$500.00
|
|
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2012', provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) therapeutic pipeline. This
|
more...
|
$500.00
|
|
Epidemiology: Asthma
9/22/2011 | published by: Datamonitor
Overview of asthma definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10-year prevalent case forecast, and key patient segments across the seven major markets. Introduction Datamonitor estimates that there
|
more...
|
$5,700.00
|
|
Asthma - Executive Market Summary 2011
6/3/2011 | published by: Timely Data Resources, Inc.
The Asthma Executive Market Summary 2011 provides an overview of the disease and related conditions, with incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatment.
|
more...
|
$995.00
|
|
Novel Drug Targets and Strategies for Asthma and Chronic Obstructive Pulmonary Disease
9/1/2011 | published by: Decision Resources
Asthma and chronic obstructive pulmonary disease (COPD) are inflammatory diseases that share many characteristics, such as breathlessness, coughing, and airway obstruction; these diseases are treated with many of the same or same types of therapies.
|
more...
|
$4,600.00
|
|
Epidemiology: COPD - Aging population and stable smoking rates to raise case numbers
8/17/2011 | published by: Datamonitor
Introduction In 2010, Datamonitor estimates that there were about 69.5 million total prevalent cases of chronic obstructive pulmonary disease (COPD) in people aged over 40 in the seven major markets(the US, Japan, France, Germany, Italy, Spain,
|
more...
|
$5,700.00
|
|
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
8/31/2011 | published by: GlobalData
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Summary GlobalData, the industry analysis specialist, has released its new report, “Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Pipeline Assessment and Market Forecasts
|
more...
|
$3,500.00
|
|
Asthma and COPD Therapies: World Market 2011-2021
8/8/2011 | published by: Visiongain
How will the market for asthma and COPD treatments perform from 2011? Our new report shows you potential drug revenues to 2021, discussing opportunities and market prospects.
Discover potential asthma and COPD
|
more...
|
$2,331.00
|
|
Special Report: The Pricing and Reimbursement Environment for Respiratory Disease Therapies
10/1/2011 | published by: Decision Resources
Common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) make up a large and varied pharmaceutical market sector. These diseases also impose a significant burden on patients, providers, and payers, putting them
|
more...
|
$4,600.00
|
Related Markets
Asthma Reports
- Asthma Global Clinical Trials Review, H2, 2011
- Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD
- China Asthmatic Prescription Drugs Sales Data 2006-2010
- Industry Outlook: Trends in Respiratory Disease Strategies
- Special Report: The Pricing and Reimbursement Environment for Respiratory Disease Therapies
